Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials-Reference-Cited by-同舟云学术

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Published:2006-08 Issue:9534 Volume:368 Page:466-475
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hicks Charles B,Cahn Pedro,Cooper David A,Walmsley Sharon L,Katlama Christine,Clotet Bonaventura,Lazzarin Adriano,Johnson Margaret A,Neubacher Dietmar,Mayers Douglas,Valdez Hernan

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Determinants of virological response to antiretroviral therapy: implications for long-term strategies;Deeks;Clin Infect Dis,2000

2. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group;Mocroft;J Infect Dis,2004

3. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes;Ledergerber;Lancet,2004

4. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class;Turner;J Med Chem,1998

5. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor;Poppe;Antimicrob Agents Chemother,1997

Cited by 281 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and clinical characteristics of people with HIV with limited treatment options in Japan: A Japanese claims data analysis;Journal of Infection and Chemotherapy;2024-06

2. Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023;European Journal of Medicinal Chemistry;2023-10

3. Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union;International Journal of Pharmaceutics;2023-07

4. The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review;Antiviral Therapy;2023-05-22

5. Virtual screening identifies tipranavir as a SIRT1 inhibitor with anti-hepatocarcinoma effect;Future Medicinal Chemistry;2023-03